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Aims: The use of biodegradable-polymer drug-eluting stents has been shown to provide
favorable results when compared with durable polymer drug-eluting stents and long-term
follow up data have recently shown significant reductions in terms of very late stent
thrombosis.
Aim of the present study was to assess the safety and efficacy profile of a novel
biodegradable polymer DES, the Yukon Choice Flex sirolimus-eluting stent.
Methods: We report here the one-year clinical outcomes associated with the use of the Yukon
Choice Flex sirolimus-eluting stent in an all-comers patient population. The present stent
represents a further refinement of the stent platform tested in the ISAR TEST 3 and 4 ran-
domizedclinical trials.A totalof778consecutivepatientsundergoing implantationof thisstent
were enrolled in the present observational study and prospectively followed for one year.
Results: The use of the Yukon Choice Flex stent in a patient population with complex
coronary lesion morphology was associated with optimal immediate angiographic results.
At one year follow up the rates of death, myocardial infarction, definite stent thrombosis
and ischemia-driven target lesion revascularization were respectively 2.4%, 1.9%, 0.3% and
11.3%.
Conclusions: The use of the sirolimus-eluting biodegradable polymer Yukon Choice Flex
stent in an all-comers population of patients with complex coronary artery disease is
associated with a favorable safety and efficacy profile up to one year follow up.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
The introduction of drug-eluting stents (DES) in clinical prac-
tice has led to a drastic reduction in the rates of restenosis and77.
. Kastrati).
ociety of India. All rightsthe need for repeat revascularization procedures.1e3 However,
an increase in the incidence of very late stent thrombosis
associated with the use of early generation DES compared
with BMS has been reported,4,5 particularly among patients
with off-label indications.6,7 Despite the increase in thereserved.
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limited in absolute terms, owing to the poor outcomes asso-
ciated with this clinical entity, considerable efforts have been
directed to clarify its underlying pathobiological mechanisms
and to reduce its incidence. Animal experiments and human
autopsy studies have shown that very late stent thrombosis is
related to delayed arterial healing and remodeling of the
stented vessel owing to ongoing inflammation.8e11 Particu-
larly, the persistence of the polymer coating on the stent
surface after completion of the drug-elution process, has been
shown to act as a trigger for a chronic inflammatory response,
which delays the process of stent coverage and predisposes to
late thrombotic events.12,13 Since the function of the polymer
coating is limited to that of a reservoir which allows for drug
loading and modification of the release kinetics of the anti-
proliferative drug, the use of biodegradable polymer coat-
ings, which undergo a process of absorption once their role
has been served, seems particularly attractive, since it would
eliminate the stimulus for the chronic inflammatory
response, leading to a more favorable tissue healing profile
and potentially reducing the rates of very late stent
thrombosis.
Accordingly, biodegradable polymer DES have been devel-
oped and compared with durable polymer DES in randomized
clinical settings and the favorable outcomes associated with
their use have provided support to the initially hypothesized
advantages associated with their use.14e16 Owing to these
favorable results, great interest and hope has been associated
with this new generation of stents, which could further
improve the safety and efficacy of percutaneous coronary in-
terventions (PCI).
We report here the one-year outcomes associated with the
use of a novel biodegradable polymer DES, the Yukon Choice
Flex sirolimus-eluting stent (Translumina Therapeutics), in an
unselected population cohort.2. Methods
Patients presenting with ischemic symptoms or signs of
myocardial ischemia in the presence of 50% coronary ste-
nosis were considered eligible, provided that written,
informed consent by the patient or her/his legally authorized
representative was obtained. Besides age 18 years, there
were no adjunctive exclusion criteria to patient enrollment in
this prospective observational study.
The Yukon Choice Flex stent is a new generation stent
consisting of a cobaltechromium backbone (79 mm thickness)
and a biodegradable polymer (polylactic acid) applied on the
stent surface, which allows a controlled release of the anti-
proliferative drug followed by a bioresorption process of the
polymer coating over a period of 6e9weeks. The eluted drug is
represented by sirolimus, a highly effective and widely tested
agent with immunosuppressive and antimitotic properties,
which has consistently shown superior outcomes compared
with the paclitaxel-eluting stent platforms in terms of neo-
intimal proliferation inhibition and repeat revascularization
procedures.17,18
During the procedure, patients were given intravenous
aspirin, heparin or bivalirudin; glycoprotein IIb/IIIa inhibitorswere used at the discretion of the operator. After the inter-
vention, all patients received aspirin indefinitely, clopidogrel,
prasugrel or ticagrelor for at least 12months and other cardiac
medications according to the judgment of the patient’s
physician [b-blockers, ACE (angiotensin-converting enzyme)-
inhibitors, statins etc.]. Patients remained in the hospital for
at least 48 h. Blood samples were drawn every 8 h for the first
24 h and daily afterward for the determination of cardiac
markers (CK, CK-MB, Troponin T) and blood cell counts (he-
moglobin, hematocrit, platelet count, white blood cell count).
Daily recording of ECG was also performed until discharge.
Relevant data were collected and entered into a computer
database by specialized personnel of the Clinical Data Man-
agement Center. Baseline and post-procedural cineangio-
grams were forwarded to the Quantitative Angiographic Core
Laboratory (DeutschesHerzzentrum, Munich, Germany) for
assessment by experienced operators. Angiographic image
acquisition of the target lesion was done after intracoronary
administration of nitroglycerin and the measurements were
performed in the same single worst view projection. The off-
line quantitative coronary angiographic analysis was per-
formedwith an automated edge-detection system (QAngio XA
7,1; Medis, Medical Imaging Systems). The contrast filled, non-
tapered catheter tip was used for calibration. The reference
diameter was measured by interpolation. Minimal lumen
diameter wasmeasured within the stent andwithin the 5mm
proximal and distal edges of the stent. Quantitative analysis
was performed in the in-stent area (in-stent analysis) and in
the in-segment area including the stented segment, as well as
both 5 mm margins proximal and distal to the stent (in-
segment analysis). Qualitative morphological lesion charac-
teristics were characterized by standard criteria.19
2.1. Statistical analysis
Categorical variables are summarized as counts or pro-
portions (%) whereas continuous variables are expressed as
mean  SD or median with 25th and 75th percentiles. Data
distribution was tested for normality using the Kolmogor-
oveSmirnov test. Survival was assessed using the
KaplaneMeier method.3. Results
3.1. Baseline characteristics and procedural results
A total of 778 consecutive patients undergoing coronary im-
plantation of the Yukon Choice Flex sirolimus-eluting stent in
our center were enrolled in the present study and considered
for the present analysis.
Baseline clinical characteristics of the patient population
are shown in Table 1. Overall, there is a high prevalence of
coronary risk factors and 26.1% of patients had diabetes
mellitus. Moreover, a high percentage of patients (40.9%) dis-
played unstable coronary syndromes and multivessel disease
was present in 83% of the patient population.
A total of 1440 lesions were treated (1.85 lesions/patient).
Baseline angiographic characteristics are displayed in Table 2
and are notable for a high prevalence of complex lesion
Table 2 e Baseline angiographic characteristics.
Target vessel
Left main 35 (2.4)
LAD 621 (43.1)
LCX 354 (24.6)
RCA 421 (29.2)
Venous bypass 6 (0.4)
Arterial bypass 3 (0.2)
Ostial lesion 339 (23.5)
Bifurcational lesion 467 (32.4)
Total occlusion 173 (12.0)
Chronic occlusion 80 (5.6)
Complex morphologya 1059 (73.5)
Values shown represent numbers (percentages).
LAD, left anterior descending artery; LCX, left circumflex
artery; RCA, right coronary artery.
a Defined as type B2/C by AHA/ACC classification.
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stent was successful in all lesions and the immediate angio-
graphic outcomes were excellent (Table 3). The mean stented
length was 26.9  12.9 mm.
3.2. Clinical outcomes
Clinical follow up was performed for all patients up to one-
year.
During the first 30 days of follow up, 6 (0.8%) patients died,
4 (0.5%) patients suffered a transmural myocardial infarction
and 7 (0.9%) patients suffered a non-transmural myocardial
infarction; a sub-acute stent thrombosis occurred in 2 (0.3%)
patients. Death or myocardial infarction occurred during the
first 30 days in 15 (1.9%) patients.
By 12 months, 19 (2.4%) patients died, 4 (0.5%) patients
suffered a Q-wave myocardial infarction and 11 (1.4%) pa-
tients a non Q-wave myocardial infarction; ischemia-driven
target lesion revascularization occurred in 163 (11.3%) le-
sions. Death or myocardial infarction at 1-year follow up
occurred in 32 (4.1%) of patients (Table 4)4. Discussion
In this prospective observational study we report the 1-year
clinical outcomes associated with the use of the Yukon
Choice Flex sirolimus-eluting coronary stent in the treatment
of coronary artery disease. The study cohort represents an all-Table 1 e Baseline patient characteristics.
Age (years), mean  SD 68.2  10.7
Male 580 (74.6)
BMI, mean  SD 27.8  4.6
Diabetes 203 (26.1)
Insulin-requiring 70 (9.0)
Tablet-controlled 111 (14.3)
Hypertension 527 (67.7)
Hyperlipidemia 620 (79.7)
Current smoker 129 (16.5)
Prior MI 202 (25.9)
Prior PCI 398 (51.2)
Prior bypass surgery 71 (9.1)
EF, mean  SD 52.9  11.5
Clinical presentation
STEMI 86 (11.1)
NSTEMI 111 (14.3)
Unstable angina 121 (15.5)
Stable angina 452 (58.1)
Silent ischemia 8 (1.0)
Coronary disease
Single vessel 132 (16.9)
Two vessel 203 (26.1)
Three vessel 443 (56.9)
Multivessel disease 646 (83.0)
Values shown represent numbers (percentages) unless
otherwise indicated.
BMI, body mass index; MI, myocardial infarction; NSTEMI,
non ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial
infarction.comers patient population, thereby reflecting real clinical
practice and allowing to test the device in a real-world setting.
Accordingly, the study population comprised a cohort of pa-
tients with complex coronary lesion morphology (73.5% type
B2/C lesions according to the ACC/AHA classification), a high
prevalence of diabetes mellitus (26.1%), multivessel disease
(83.0%) and of unstable coronary syndromes (40.9%).
The safety and efficacy of coronary artery stent platforms
is modulated by each of their components, namely the stent
design, the anti-proliferative drug and the presence and type
of polymer. The performance of the precursor of the present
biodegradable polymer DES was previously tested in the pro-
spective, randomized ISAR TEST 3 and ISAR TEST 4 trials, as
part of the ISAR (individualizable drug-eluting stent system to
abrogate restenosis) stent project, aiming at investigating
novel DES coatings with high restenotic efficacy and without
the untoward effects of durable polymer coatings.14,15,20,21 The
biodegradable polymer DES used in these trials, displayed a
pre-mounted, sand blasted, 316L stainless steel microporous
backbone which was coated on site with a mixture of rapa-
mycin, biodegradable polymer and shellac resin. The Yukon
Choice Flex sirolimus-eluting stent represents an evolution of
the previous stent used in the ISAR TEST 3 and 4 trials. The
main differences are represented by the standardization of
the coating process, which is now performed on an industrial
basis and the use of a cobaltechromium backbone, withTable 3 e Lesion and procedural characteristics.
Lesion length, mm 17.2  10.5
Reference diameter, mm 2.87  0.53
MLD, pre-procedure, mm 0.91  0.49
Stenosis, pre-procedure, % 68.5  14.8
Maximum balloon diameter 3.12  0.58
Balloon-to-vessel ratio 1.11  0.09
Maximal balloon pressure, a.t.m. 14.8  3.35
Stented length, mm 26.9  12.9
Stent diameter, mm 3.04  0.47
MLD post, mm 2.56  0.55
Stenosis post, % 14.2  10.6
Data are shown as mean  SD.
MLD, minimal lumen diameter.
Table 4 e Clinical follow-up data at 1 month and 1-year.
30 days 1-year
Death 6 (0.8) 19 (2.4)
Myocardial infarction 11 (1.4) 15 (1.9)
Q-wave 4 (0.5) 4 (0.5)
Non Q-wave 7 (0.9) 11 (1.4)
Death/MI 15 (1.9) 32 (4.1)
Definite stent thrombosis 2 (0.3) 2 (0.3)
TLR 163 (11.3)
Re-PCI 156 (10.8)
CABG 7 (0.4)
Values shown are numbers (percentages).
CABG, coronary artery bypass grafting; MACE, major adverse car-
diac events; MI, myocardial infarction; PCI, Percutaneous coronary
intervention; TLR, target lesion revascularization.
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increased stent flexibility without compromising its radial
strength. The modification of the stent platform was under-
taken in an attempt to overcome some of the limitations
associated with the use of stainless steel stent platforms and
in particular to improve stent deliverability, especially in case
of unfavorable lesion characteristics, such as vessel tortuos-
ity, complex lesion anatomy and lesion calcifications.
The results of the present study show that the use of this
stent platform is feasible and associated with optimal imme-
diate angiographic results. Moreover, despite the complexity
of the clinical and angiographic profile of the present patient
population, its use is associated with a favorable 1-year safety
and efficacy profile. Compared with the Resolute All Comers
Trial,22 a large randomized non-inferiority trial with minimal
exclusion criteria comparing two new-generation durable
polymer DES, we observed a lower rate of myocardial infarc-
tion (1.9% versus 4.2%) and definite stent thrombosis (0.3%
versus 0.75%) at 1-year follow up; instead, the rate of target
lesion revascularization was higher in our study (11.3% versus
3.65%). A possible explanation for the observed difference
might be provided by the higher grade of severity of coronary
artery disease in the population included in the present study
(multivessel disease 83% versus 58.8%; mean lesion length
17.2 mm versus 12.0 mm).
The biodegradable nature of the polymer could be expected
to confer superior outcomes associatedwith theYukonChoice
Flex sirolimus-eluting stent compared with the previous gen-
eration of durable polymer DES, especially in terms of the
incidence of very late in-stent thrombosis. Despite biode-
gradable polymer DES being initially developed with this pre-
cisefinality, a clear superioritywith respect to durablepolymer
DES in termsof reductions of definite stent thrombosiswasnot
immediately evident in the randomized controlled trials
comparing durable and biodegradable polymer stent plat-
forms.23,24 Indeed, the clinical advantage associated with the
use of biodegradable polymer DES is expected to emerge only
during long term follow up, after complete absorption of the
polymer. Accordingly, large numbers of patients and long
follow up periods are required to capture differences in terms
of a relatively rare phenomenon such as very late stent
thrombosis. However, evidence of a favorable pattern of arte-
rial healing associated with the use of biodegradable polymerDES,was already reported in an optical coherence tomography
substudy of the LEADERS Trial, reportingmore complete stent
strut coverage in the group of patients treated with the
biodegradable polymer DES comparedwith those treated with
durable polymer DES at 9months follow up.25 More recently, a
pooled analysis of individual patient data from the threemajor
randomized trials comparing bioresorbable-polymer and du-
rable polymer DES (ISAR TEST 3, ISAR TEST 4 and LEADERS
Trials)with anextended followupup to 4 years, showed for the
first time a significant reduction in terms of definite stent
thrombosis in favor of biodegradable polymer DES.26 These
conclusions received further support by the recent release of
the 5-year followupdataof the LEADERSTrial,whichconfirma
significant superiority of the biodegradable polymer DES
compared with the durable polymer DES, driven primarily by
the reduction in the incidence of very late thrombotic events.27
In our study, a very low incidence of definite stent thrombosis
events (0.3%) was observed. The one year follow up of the
present observational studydoesnot allow to capture eventual
benefits in terms of very late thrombotic events. Despite the
lack at the present moment of a clear proof of benefit in terms
of very late thrombotic event reduction, it seems reasonable to
hypothesize that the incorporation of a biodegradable polymer
could represent an adjunctive favorable characteristic of the
present stent platform. However, definite conclusions in this
regard require a direct comparison of the present stent plat-
form with durable polymer DES in a randomized clinical
setting.
Routine control angiography was not part of the present
study, thereby no definitive conclusions can be drawn relating
to the antirestenotic efficacy of this stent platform. However,
the low event rates and the favorable clinical follow up of the
present population represent an indirect proof of the anti-
restenotic efficacy of this stent platform.
In conclusion, this prospective observational study shows
that the use of the Yukon Choice Flex sirolimus-eluting stent
in an all-comers patient population with complex coronary
lesion morphology is feasible and associated with a favorable
1-year safety and efficacy profile. Its use could therefore
represent a valuable adjunct in the field of the contemporary
interventional cardiology.Conflicts of interest
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